INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) has been used to treat patients with various malignant and nonmalignant diseases during the last 40 years. In 1957, Thomas et al. 1 first reported the infusion of bone marrow (BM) into patients who received radiation and chemotherapy. These early experiences led to the use of allogeneic HSCT to promote recovery of hematopoietic function after myeloablative therapy. In 1968, the first successful human BM transplantion (BMT) was performed by Park et al. 2 By the late 1970s, Thomas et al. 3 used allogenic BM from human leukocyte antigen (HLA)-identical siblings, following total body irradiation (TBI) and administration of cyclophosphamide. In vivo transplantation of BM elements suggested that mesenchymal stem cells (MSCs) were precursors to BM connective tissue cells. In the 1990s, nonmyeloablative stem cell transplant was used for hematologic diseases and solid tumors. 4, 5 Kessinger et al. 6, 7 introduced the use of peripheral blood stem cells for allogeneic transplant.
The history of stem cells began with the discovery in the mid-1800s that some cells had the ability to generate other cells. 8 Stem cell studies were performed by Maximow and Friedenstein. 9, 10 Maximow discovered stem cells in the blood that could differentiate into various blood cells, and observed the relationship between hematopoiesis and the mesoderm during development. 9 Friedenstein first isolated adult nonhematopoietic stem cells from the BM and demonstrated ectopic BM formation by transplanting marrow stromal cells. 11 In the 1970s, Friedenstein et al. 10 first isolated adherent stromal cells from whole BM in vitro culture. These adherent stromal cells were fibroblast-like, clonogenic cells with multilineage potential to differentiate into different mesenchymal tissues and hematopoietic-supporting stroma when a single colony-forming unit-fibroblast (CFU-F) was retransplanted in vivo. 10 In the 1980s, Caplan and Owen further refined isolation methods and identified MSC markers. 12, 13 In 1998, Thomson et al. 14 isolated cells from the inner cell mass of early embryos and developed the first human embryonic stem cell lines. 14 Gearhart derived germ cells from fetal gonad tissue. 15 Following the discovery of isolation and culture methods for MSCs, MSC-based therapies for stem cell research and clinical application began to be developed. MSCs have gained attention due to their potential for cell therapy and regenerative medicine. Recently, studies of the immune-suppressive capacity and regenerative potential of MSCs have generated clinical interest in the field of HSCT in terms of preventing graft rejection and controlling graft-versus-host disease (GVHD), as well as facilitating tissue engineering.
DEFINITION OF MSCS
MSCs, also known as mesenchymal stromal/stem cells, are non-hematopoietic. They were originally defined as self-renewing, multipotent progenitor cells with multilineage potential to differentiate into other types of cells of mesoderm origin, such as adipocytes, osteocytes, chondrocytes, tenocytes and skeletal myocytes, as well as cells of non-mesodermal origin, such as hepatocytes, neural cells and epithelial cells. [16] [17] [18] [19] MSCs were initially identified in the BM and are commonly isolated by gradient centrifugation to separate nucleated cells, followed by in vitro culture and serial passage. However, many publications suggested the lack of 'stemness' of MSCs. 20 To improve the definition of MSCs, the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy (ISCT) designated the name 'multipotent mesenchymal stromal cells' for the plastic-adherent cells found under standard culture conditions. 20 The surface phenotype of culture-expanded MSCs, by the defined ISCT standards, is negative for surface CD14 or CD11b, CD45, CD34, CD79 or CD19, and HLA-DR. MSCs are generally, but not homogeneously, positive for a number of cell-surface markers, including CD73, CD90 and CD105. Also, MSCs must differentiate into bone, fat and cartilage by addition of exogenous growth factors, and must be plastic-adherent in vitro. 21 Additionally, MSCs uniformly express CD49b, CD49e, CD54, CD166, CD50, CD62L and CD106. MSCs lack expression of the co-stimulatory molecules CD80, CD86, CD40 and CD40L. 22, 23 Expression of chemokine receptors, including CCR1, CCR7, CXCR4, CXCR5 and the chemokine CX 3 CL1, by late-expanded MSCs is downregulated compared with that of early-passage expanded MSCs. 24 The expression of surface antigens, including GD2, CD271 and frizzled-9, on MSCs has led to the isolation of MSCs using antibody-based immunomagnetic beads and/or fluorescence-activated cell sorting. [25] [26] [27] [28] The phenotypic markers of MSCs are summarized in Table 1 ; however, no single marker that definitively distinguishes MSCs from all other cell types has been identified.
Although MSCs can differentiate into various mature cells, their intrinsic capacity to secrete cytokines and growth factors at sites of tissue injury and inflammation contributes significantly to their therapeutic capacity. The production of these tropic mediators is defined by their in vivo location, niche and severity of injury. MSCs are reservoirs for the production of cytokines, chemokines and extracellular matrix components, which have the ability to support stem cell survival and proliferation. 27, 29, 30 MSCs possess differentiation potential and may regenerate damaged or diseased tissues in vivo, as well as have a potential role in immunomodulation, providing a basis for a variety of clinical applications.
SOURCE OF MSCS
MSCs are most commonly isolated from BM, 17 but stromal cells with identical properties of BM-derived MSCs have been identified in many other tissues. These cells have been obtained from adipose tissue, [31] [32] [33] placenta, 34 amniotic fluid, [35] [36] [37] [38] umbilical cord blood (UCB), 39, 40 connective tissues of skeletal muscle and dermis, 41 dental tissue, 42 and fetal tissues such as lung and blood. 35 Mobilized peripheral blood cells have also been reported as a source of MSCs. 43 Although reports of UCB as a source of MSCs were initially controversial, there is general agreement that MSCs do reside within cord blood and that the volume and storage time of the cord blood are critical for successful isolation of MSCs. 39 The developmental relationship between these different MSCs has not yet been determined, and there is no consensus as to whether BM-derived MSCs are the same as those isolated from other tissues. Gene expression studies have demonstrated that MSC populations are highly heterogeneous, including those from the same tissue source. 44 Thus, MSC gene expression profiles, including expression levels of MSC markers and some of their functional properties, differ according to the tissue source. 45 With regard to their ability to renew and differentiate, all cells derived from the majority of tissues behave in a similar manner. Additionally, the major functional properties, such as regulation of immunological tolerance, wound healing, inflammation and fibrosis, are common to all MSCs. 46 The heterogeneity of the MSC population suggests that different tissue sources may generate MSCs particularly suited to specific clinical applications.
IMMUNOMODULATORY PROPERTIES OF MSCS
MSCs not only provide stromal support for hematopoietic stem cells in the BM but also have potent immunosuppressive and anti-inflammatory effects. MSCs suppress T-cell proliferation induced by alloantigens or mitogens via increasing the number of regulatory T cells. 47, 48 The interactions between T cells and MSCs have significant clinical implications in HSCT. MSCs have been shown to lessen complications of GVHD after HSCT 49 and immune-mediated disease. [50] [51] [52] In addition, MSCs inhibit function of B cells, 53 natural killer cells 54 and dendritic cells. 55 The main immunosuppressive function of MSCs is to induce soluble factors, including transforming growth factor-b, 56 hepatocyte growth factor, 57 nitric oxide, 58 HLA-G 59 and indoleamine 2,3-dioxygenase 60 (Table 2) ; however, these cells can also exert immunosuppressive effects by direct cell-to-cell interaction. 61 The immunosuppressive capacity of MSCs is enhanced under inflammatory conditions in the presence of the proinflammatory cytokines interferon (IFN)-g, tumor necrosis factor-a and interleukin (IL)-6. MSCs constitutively produce large amounts of IL-6 and IL-8, and the chemokine CCL-2. When MSCs were treated with IFN-g, there was secretion of ICAM-1, CXCL-10 and CCL-8, whereas IL-8 production was decreased. 62 This phenomenon suggests that MSCs target neutrophils and monocytes under non-inflammatory conditions, but attract monocytes, dendritic cells, T cells and natural killer cells under inflammatory conditions. 62 A number of studies reported transforming growth factor-b as a key mediator of immunomodulation by MSCs. There is some evidence that the transforming growth factor-b-transduced MSCs used in our study showed enhanced immunomodulatory effects on T-cell-mediated immunity. 56 Under immunologically quiescent conditions, MSCs promote T-cell survival and can induce the activation and proliferation of CD4 þ T cells. 63, 64 The dual immunomodulatory properties of MSCs suggest that environmental factors may have a crucial role in induction of MSC-mediated immunomodulation.
Recent studies reported that MSCs must be 'licensed' to exert their immunomodulatory effects. Marigo and Dazzi 65 showed that MSCs are not constitutively inhibitory, but require a licensing step to produce acute inflammatory helper T-lymphocyte (Th1)-type cytokines. If MSCs are transplanted during acute inflammation, the microenvironment containing polarized M1 macrophages 'licenses' MSCs to inhibit effector T, B, natural killer and dendritic cells. In contrast, if MSCs are licensed after the polarization of M2 macophages by Th2-type cytokines during chronic inflammation, the microenvironment provides alternative licensing and recruits MSCs to the fibrosis process. 65 In conclusion, MSC therapy in an inflammatory microenvironment that is licensing-dependent. Under conditions of mild or chronic inflammation, the lack of licensing fails to provide therapeutic effects, leading to weakened MSC immunosuppressive activity.
THERAPEUTIC POTENTIAL OF MSCS FOR TREATMENT OF ACUTE AND CHRONIC GVHD
GVHD is a severe inflammatory condition, which results from immune-mediated attack of recipient tissue by donor T cells contained in the allogeneic graft. The immunomodulatory properties of MSCs have led to clinical trials of MSC-based therapy to prevent acute GVHD (aGVHD) and chronic GVHD (cGVHD), major complications that occur after allogeneic HSCT. 66 For a more detailed review of GVHD, see Schroeder and DiPersio. 67 Without intervention before HSCT, almost all allotransplant recipients develop significant GVHD. These data suggest that enhancing the immunomodulatory capacity of MSCs has potential for treatment of GVHD following HSCT. 68 Multiple drugs and strategies are used to deplete T cells to prevent donor anti-host immunological complications of allotransplantation. Recently, the immunomodulatory and tissue-repair properties of MSCs have led to many studies and clinical trials of their use as a treatment for GVHD. The rationale for studies of MSCs was based on their immunomodulatory properties identified by numerous in vitro assays and in vivo models, as explained above. aGVHD involves direct cytotoxic effects of donor T cells on recipient tissues, activation of antigen-presenting cells and an inflammatory cascade that produces cytokines, including IL-1, IL-6, IL-12, IFN-g and tumor necrosis factor-a. 69 At first, there was a scarcity of preclinical models demonstrating the efficacy of MSCs in ameliorating aGVHD before clinical studies started. In fact, most preclinical models were developed after the demonstration of clinical efficacy. The clinical efficacy of MSCs in aGVHD was initially observed in a 9-year-old boy suffering from steroid-resistant grade IV aGVHD who received haploidentical third-party MSCs. 70 In the next phase II clinical trial, which involved 55 patients with the same condition, the administration of MSCs significantly improved the overall survival rate. 71 However, in another phase I/II clinical trial, a single infusion of MSCs given at the time of the transplant did not prevent the development of aGVHD. 72 This discrepency was also seen in animal models and was later explained by the findings of preclinical studies. Initial studies of MSCs in a murine aGVHD model demonstrated that a single infusion of MSCs at the time of HSCT did not prevent aGVHD, 73 but this could be mitigated by multiple doses given at weekly intervals subsequent to HSCT. 74 Polchert et al. 75 reported that MSCs can be used to treat aGVHD when administered at an appropriate time in the presence of IFN-g. That study showed that the survival rate of mice increased when MSCs were administered at day þ 2 or þ 20 of HSCT, when IFN-g levels were at their peak. This study demonstrated that timing was critical because an appropriate inflammatory environment was needed to 'license' the MSCs. The role of IFN-g and of the inflammatory environment in activation of MSCs to exhibit inhibitory activty has been described in vitro. 76 It has been suggested that inflammatory cytokines, including IFN-g, can recruit MSCs to the site of inflammation and tissue injury. 77 In addition to their immunomodulatory effects, MSCs might enhance the healing of wounded tissue by providing soluble factors, transdifferentiation and cell fusion. In a previous clinical trial, patients were treated with MSCs to ameliorate tissue toxicty following HSCT. 78 Tissue injuries, such as hemorrhagic cystisis and pneumomediastium, were cleared in several patients after treatment with MSCs. In one patient with aGVHD, symptoms of perforated diverticulitis and peritonitis were reversed by MSC therapy. 78 Furthermore, a series of experiment used bioimaging to track the biodistribution of MSCs in a murine model of aGVHD. 79 In these experiments, donor C57BL/6 splenocytes, which expressed enhanced green fluorescent protein, were used to induce aGVHD. Then, MSCs were generated from C57BL/6 donor mice expressing red fluorescent protein (RFP). RFP-MSC were injected, and both fluorescent signals were detected consistently. Enhanced green fluorescent protein was first detected in the lungs, but spread to the gastrointestinal (GI) tract, liver, skin, and lymph nodes, all of which are known clinical targets of aGVHD. After injection, RFP signals colocalized with EGFP signals at the aGVHD target sites, proving that MSCs can home to sites of aGVHD and potentially exert direct cell-cell contact-mediated effects as well as paracrine effects for tissue repair. Murine MSCs that were engineered to express the anti-inflammatory cytokine IL-10 significantly reduced the severity of aGVHD compared to unmodified MSCs. 80 It is likely that safely engineered MSCs may provide more targeted and effective cell therapy for aGVHD. cGVHD occurs after the first 100 days of HSCT and is characterized by autoimmune-like dysregulation. While aGVHD involves mainly the skin, liver, and GI tract, cGVHD affects almost any organ and reduces the quality of life, organ function, and overall survival. 81 In contrast to aGVHD, the pathophysiology of cGVHD is poorly understood. A clinical trial of the use of MSCs to treat cGVHD has been reported recently. 72 The first report involved co-transplantation of HLA-identical sibling culture-expanded MSCs with HLAidentical sibling HSCT in patients with hematologic malignancies. Clinical improvement was identified in 22 of 36 (61%) patients who survived at least 90 days. 72 Another report suggested that BM-derived MSCs may be used successfully to treat adult patients with sclerodermatous cGVHD, 82 because IFN-g, IL-2, IL-10, and IL-4 producing cells were detected both before and after MSC infusion. Before MSC infusion, Th2-type cells were markedly increased compared to Th1 type cells, whereas after MSC infusion, the proportion of Th1 type cells increased. 82 In another study, infusion of culture-expanded MSCs was investigated as a therapeutic approach for patients with steroid-resistant cGVHD. 68 Although 14 of 19 patients (73.7%) responded to MSC administration, only four patients showed complete remission. 68 The majority of patients showed only partial or mixed responses, suggesting that MSC may not be a potent immunomodulator in a cGVHD environment. The number of studies of use of MSCs in cGVHD is insufficient; it is apparent that unlike aGVHD, the therapeutic effect of MSCs on cGVHD is limited.
Despite in vitro and in vivo evidence that MSCs can ameliorate GVHD, clinical trials of the treatment of GVHD remain incomplete. Our recent data showed that transforming growth factor-b-transduced MSCs were able to successfully treat autoimmune arthritis by inducing Foxp3 levels and inhibiting IL-17 production; however, MSCs themselves did not suppress IL-17 production. 56 These findings suggest that while MSCs exert immunomodulatory properties via an IFN-g (thast is, Th1)-dominant response, MSCs may not effectively inhibit Th17 responses. While the role of Th17 in aGVHD pathogenesis is still not clearly defined, recent studies have revealed that GVHD involves a combination of both Th1 and Th17 responses; 83 thus, the monitoring of both Th1 and Th17 responses, rather than Th1 or Th17 responses alone, could be an accurate indicator of GVHD severity after HSCT. 84 Furthermore, Yi et al. 85 suggested that blocking Th1 or Th17 cells alone was ineffective for treatment of GVHD. Blocking Th1 cells led to the exacerbation of Th17 responses, and vice versa. Thus, new studies are proposing that simultaneous inhibition of Th1 and Th17 differentiation could be a new strategy to treat GVHD following HSCT. 86 Finally, a more standardized study design is needed for clinical trials, in order to accurately evaluate the effects of MSCs on GVHD. Data from preclinical murine GVHD models suggest that the timing of MSC administration is critical to its effectiveness, but the optimal treatment schedule has not yet been defined. To-date a variety of dosing schedules has been used; however, the optimal treatment method should be determined. Furthermore, as mentioned above, a consensus must be formed regarding the optimal culture and manufacturing conditions to generate uniform MSCs. Therefore, more definitive studies and longer follow-ups during clinical trials are necessary to assess the long-term efficacy and toxicity associated with MSC use. In future studies, the use of genetically modified MSCs holds considerable promise. In conclusion, both preclinical (Table 3) and clinical (Table 4) trials using MSCs as a potential therapeutic agent for the treatment of GVHD are encouraging, yet the data remain incomplete.
FACILITATING ENGRAFTMENT BY MSCS
MSCs have been suggested to be the progenitor cells that modulate alloreactivity and promote hematopoietic reconstitution. Therefore, MSCs have been suggested to enhance aGVHD, acute graft-versus-host diasease; BM, bone marrow; CIA, collagen-induced arthritis; GVHD, graft-versus-host diasease; HSCT, hematopoietic stem cell transplantation; IL-10, interleukin 10; MSC, mesenchymal stem cell; TGF-b, transforming growth factor-b. aGVHD, acute GVHD; BM, bone marrow; cGVHD, chronic GVHD; CR, complete response; MSC, mesenchymal stem cell; PBSC, peripheral blood stem cell; PR, partial response.
Potential use of MSCs in HSCT E-J Kim et al engraftment and to prevent rejection after HSCT. Co-transplantation of fetal and adult human MSCs promoted longterm engraftment in immunodeficient (non-obese diabetic/ SCID) mice and fetal sheep. 87, 88 Infusion of allogeneic BMderived MSCs inhibited lymphocyte proliferation and prolonged skin allograft survival. 89 Co-transplantation with MSCs improved HSC engraftment after autologous intra-BM (IBM) transplantation in non-human primates. 90 In murine models, the infusion of host MSCs enhanced engraftment of allogeneic hematopoietic cells; however, donor MSCs increased rejection of an allogeneic stem cell graft. 91 During the first clinical trial, rapid hematopoietic recovery was accelerated by the use of culture-expanded marrow MSCs and autologous blood transplantation. 92 In a phase I/II clinical trial, cotransplantation of donor MSCs in 14 children given T-celldepleted HLA-disparate CD34 þ cells accelerated leukocyte recovery and prevented graft rejection. 93 In a pediatric phase I/II trial, infusion of ex vivo culture-expanded thirdparty haploidentical MSCs into unrelated pediatric UCB transplantation prompted hematopoietic recovery. 94 Co-infusion of parental MSCs in pediatric patients given allogeneic UCB graft prevented aGVHD, but did not affect engraftment or hematopoietic recovery. 94, 95 In an adult phase I/II clinical trial, patients receiving UCB transplantation with co-infusion of third-party donor, mobilized hematopoietic stem cells did not affect the kinetics of engraftment or aGVHD. 96 These findings indicate that co-infusion of hematopoietic cells and MSCs is safe in vivo and clinically, while the engraftment capacity of MSCs in terms of efficacy remains uncertain.
INDUCTION OF MIXED CHIMERISM USING MSCS
Induction of mixed chimerism and achieving immunological tolerance is an important goal in the efforts to reduce the morbidity, mortality and shortage of organ transplants as well as to combat hematological malignancies. Mixed chimerism entails coexistence of recipient and donor hematopoietic cells following transplantation of donor BM into conditioned recipients. These protocols involve T-cell depletion, co-stimulation blockade and therapeutic use of regulatory T cells. 97 Recent studies of MSC-mediated anti-GVHD effects, their supportive role in hematopoietic engraftment and their immunomodulatory properties have led to increasing use of MSCs in mixed chimerism protocols.
Most mixed chimerism protocols utilizing MSCs use recipient conditioning regimens to enhance the engraftment of donor BM followed by the co-administration of BM cells and MSCs. In non-obese diabetic mouse models, known to be highly resistant to chimerism induction, recipient mice were treated with a preconditioning regimen consisting of 3 Gy TBI and anti-CD3 monoclonal antibody injection. 98 The coinjection of allogeneic BM cells and MSCs facilitated engraftment, induced mixed chimerism with a success rate greater than 78%, and prevented insulitis and the onset of diabetes. Furthermore, no GVHD developed with this treatment regimen. Similar results were demonstrated in streptozotocin-diabetic rats. 99 The recipient rats received a conditioning regimen consisting of anti-lymphocyte serum and 5 Gy TBI, followed by co-infusion of allogeneic MSCs, BM cells and islets. Although all recipients rejected the islets initially, half developed stable mixed chimerism and donorspecific immune tolerance, shown by donor skin engraftment and a second round of islet transplants. In another experiment, recipient Lewis rats received a similar conditioning regimen consisting of anti-lymphocyte serum, rapamycin immunosuppressive therapy (from days 0 to 130) and 3 Gy TBI, followed by co-infusion of allogeneic MSCs and BM cells. 100 Additionally, a hindlimb allotransplant was performed 30 days after the BMT. The immunosuppressive therapy was stopped 100 days after hindlimb transplantations. Fourteen of fifteen recipients developed stable and high-level chimerism, and the survival time of hindlimb allografts was prolonged even after the withdrawal of rapamycin in the group with coadministration of MSCs. In contrast, a protocol that induced mixed chimerism with no cytotoxic conditioning was evaluated. 101 Wang et al. 101 established mixed chimerism by IBM-BMT combined with BM-derived allogeneic MSC treatment in mice. IBM-BMT is a method that administers donor BM directly into the recipient BM. Because of the low morbidity of GVHD and rapid recovery of hematopoietic function, IBM-BMT is considered one of the best strategies, and intraosseous infusion is an established method for patients receiving critical care in the clinical setting. The donor-derived MSCs were transplanted intravenously daily for 4 days before the actual transplantation, and IBM-BMT was performed immediately after the fourth injection. The majority of the mice developed 20-25% chimerism levels among myeloid lineage cells, whereas no chimerism was detected in either control group (IBM-BMT or BM-MSC treatment alone).
MSC IMMUNOGENICITY
MSCs are considered to be immunoprivileged because of their absent or low expression of major histocompatibility complex class II and other co-stimulatory molecules. MSCs have also been found to have an immunosuppressive role. Thus, MSCs have been assumed to be a powerful therapeutic tool that could be used regardless of the major histocompatibility complex identity between donor and recipient. However, recent research has revealed that MSCs can stimulate immune responses under certain conditions. Depending on the IFN-g level, MSCs can exhibit antigen-presenting properties. 102 At low IFN-g levels, MSCs can upregulate the expression of major histocompatibility complex II and gain the ability to act as an antigen-presenting cell. 102 IFN-g-treated MSCs have also been demonstrated to induce ovalbumin-specific immune responses. 103 The IFN-g-treated syngeneic MSCs could process the ovalbumin antigen peptide, present it on major histocompatibility complex II molecules, and activate ovalbumin-specific T cells. 103 MSC immunogenicity has also been demonstrated in vivo models. The presence of allogeneic MSCs in a non-myeloablative transplantation setting resulted in a significantly increased graft rejection. 91, 104, 105 Furthermore, the administration of allogeneic MSCs induced T-cell responses in naive immunocompetent host mice. It appears that MSCs can engraft immunocompromised hosts, but have limited capacity to elicit an immune response in an immunocompetent host. Many aspects of the immunogenic properties of MSCs remain to be elucidated; therefore, further studies should validate the efficacy and clinical consequences of the use of MSCs.
GRAFT-VERSUS-TUMOR EFFECT FOLLOWING MSC THERAPY
Allogeneic donor lymphocytes produce a strong graft-versustumor (GVT) effect. However, its clinical efficacy is limited by conditioning-related toxicity, GVHD, and engraftment failure. Barnes and Loutit 106 first reported GVT alloreactivity of allogeneic HSCT in a murine model. The GVT response is mediated largely by minor histocompatibility antigens, [107] [108] [109] natural killer cells [110] [111] [112] [113] and donor lymphocyte infusion. [114] [115] [116] A major focus of allogeneic HSCT is augmentation of GVT effects without GVHD. Recent investigations have focused on infusion of cells, novel pharmacologic agents and biological agents that may specifically prevent GVHD without affecting GVT reactions. More specifically relevant to GVT effects, 20 patients with hematologic malignancies received MSCs from HLA-mismatched donors after conditioning with TBI and fludarabine. 117 HLA-mismatched non-myeloablative HSCT with MSC co-infusion exhibited a therapeutic effect on the hematologic malignancies. Furthermore, the results suggested that MSC co-infusion prevented GVHD while preserving GVT effects. 117 Although the induction of tumor inhibition and enhancement are polar opposites, MSCs have numerous beneficial properties in terms of promoting GVT effects due to both their immunomodulatory properties after HSCT that may suppress tumors, as well as their tropism toward the tumor microenvironment.
CONCLUSION
HSCT was initiated in 1957 by Thomas et al. 1 by the infusion of human BM into leukemia patients. Currently, a variety of stem cell sources other than the BM, such as peripheral blood, amniotic fluid and UCB, are being used in transplantation settings, and new treatment methods are continually being discovered. However, the limitations of HSCT, including infection, relapse of disease, engraftment and complications of GVHD, have not been resolved. At present, MSCs are an excellent candidate with clinical therapeutic potential for HSCT. Preclinical and clinical studies of MSC therapy are revealing new methods of overcoming these limitations. The potential uses of MSCs include treatment of GVHD, facilitation of hematopoietic engraftment, induction of mixed chimerism and induction of the GVT effect. In addition, MSCs possess unique properties of immune modulation and tissue regeneration that highlight their potential as a potent therapeutic tool (Figure 1) . Based on the results of clinical studies, to improve the safety and efficiency of MSC therapy, studies of specific markers that identify MSCs, cell dose and the timing and route of administration are crucial and must continue. Furthermore, enhancement of the therapeutic activity of MSC transplants is required to increase our knowledge of how MSCs regulate the host immune response, and therefore, further studies may be needed to identify the immunoregulatory mechanisms and in vivo biological activities of MSCs after administration. 
